LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Closed

SectorHealthcare

440.58 -2.98

Buy Sell

Overview

Share price change

24h

Current

Min

437.79

Max

446.3

Key metrics
By Trading Economics
Income	56M -59M
Sales	34M 321M
Profit margin	-18.243
Employees	915
EBITDA	56M -50M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+58.14% upside

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	-442M 10B
Previous open	443.56
Previous close	440.58

News Sentiment

By Acuity

50%

147 / 350 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

20 mar 2026, 17:19 UTC

Major News Events

Chubb to Assume Risk, Issue Policies for $20 Billion Strait of Hormuz Insurance Facility

20 mar 2026, 16:56 UTC

Major News Events

Week Ahead for FX, Bonds: PMI Data to Show Middle East War's Impact on Sentiment

20 mar 2026, 16:56 UTC

Major News Events

Week Ahead for FX, Bonds: PMI Data to Show Middle -2-

20 mar 2026, 16:45 UTC

Major News Events

The Week in Oil: U.S. Seeks to Ease Concerns Over War But Supply Risks Mount

20 mar 2026, 16:22 UTC

Major News Events

NYMEX Overview: Petroleum Futures Rise, Leaving Most Contracts on Track for Solid Weekly Gains -- OPIS

22 mar 2026, 00:00 UTC

Earnings

Sick of High Gas Prices? EV Deals Are Everywhere Right Now -- WSJ

21 mar 2026, 08:20 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

21 mar 2026, 00:05 UTC

Acquisitions, Mergers, Takeovers

Oil, Long And Short -- Barrons.com

20 mar 2026, 20:50 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

20 mar 2026, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

20 mar 2026, 19:55 UTC

Market Talk

Major News Events

Brent Crude Closes Out Volatile Week Higher -- Market Talk

20 mar 2026, 19:28 UTC

Market Talk

Major News Events

Natural Gas Falls as Traders Sell Ahead of the Weekend -- Market Talk

20 mar 2026, 19:28 UTC

Acquisitions, Mergers, Takeovers

Ecolab Buys CoolIT Systems for $4.75 Billion. It's All About AI for the Struggling Stock. -- Barrons.com

20 mar 2026, 18:39 UTC

Market Talk

Gold Settles With Largest Weekly Dollar Decline on Record -- Market Talk

20 mar 2026, 18:31 UTC

Acquisitions, Mergers, Takeovers

Honeywell Announces Pricing of Debt Tender Offers >HON

20 mar 2026, 18:19 UTC

Acquisitions, Mergers, Takeovers

Why Mayo and Soap No Longer Mix for Unilever -- Update

20 mar 2026, 18:15 UTC

Market Talk

iMarkets May Be Wrong in Pricing for Canadian Rate Increases -- Market Talk

20 mar 2026, 17:57 UTC

Market Talk

U.S. Oil Rig Count Inches Up -- Market Talk

20 mar 2026, 17:04 UTC

Major News Events

Chubb to Assume Risk, Issue Policies for $20B Strait of Hormuz Insurance Facility

20 mar 2026, 16:20 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

20 mar 2026, 16:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

20 mar 2026, 15:40 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Unilever, McCormick Deal Makes Strategic Sense, But Risk Remains -- Market Talk

20 mar 2026, 15:30 UTC

Earnings

Gemini Space Station's Earnings 'Better Than Feared.' Can They Save the Stock? -- Barrons.com

20 mar 2026, 15:26 UTC

Market Talk

Earnings

Major News Events

Lands' End: War Impacts Weighing on Some European Consumers -- Market Talk

20 mar 2026, 15:26 UTC

Acquisitions, Mergers, Takeovers

Why Mayo and Soap No Longer Mix for Unilever -- WSJ

20 mar 2026, 15:25 UTC

Market Talk

Gilt Selloff Shows Vulnerability of U.K.'s Economy -- Market Talk

20 mar 2026, 15:19 UTC

Market Talk

Major News Events

UBS Raises Oil Price Forecast as Middle East Conflict Escalates -- Market Talk

20 mar 2026, 14:58 UTC

Major News Events

Chevron Jumps Into Top 20 Most Valuable U.S. Companies. The Iran War's Other Big Stock Movers. -- Barrons.com

20 mar 2026, 14:55 UTC

Market Talk

Major News Events

Gold Lower as Speculative Pullback Extends -- Market Talk

20 mar 2026, 14:54 UTC

Acquisitions, Mergers, Takeovers

Ecolab Buys CoolIT Systems for $4.75 Billion. It's All About AI for the Struggling Stock. -- Barrons.com

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

58.14% upside

12 Months Forecast

Average 697.67 USD 58.14%

High 964 USD

Low 529 USD

Based on 10 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

147 / 350 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.